Stabilized Vancomycin Lipid Complex for Degradation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vancomycin formulations are not cost-effective and exhibit rapid degradation, leading to stability issues, particularly in treating infections caused by multiple-resistant Staphylococcus aureus.
Innovation Solution
A stabilized lipid-based glycopeptide antibiotic composition is developed, comprising a lipid component, a glycopeptide antibiotic (such as vancomycin), and an amino acid or derivative, which forms a stabilized complex that degrades at a slower rate, enhancing stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional vancomycin formulations are used, then the treatment of Gram-positive bacterial infections is achieved, but the formulations exhibit rapid degradation and poor stability
Solution Approach 1:
The patent employs liposomal composite structures where vancomycin is encapsulated within lipid bilayers. This composite formulation protects the antibiotic from degradation while maintaining its therapeutic activity, directly addressing the stability-degradation contradiction through material composition enhancement.
Solution Approach 2:
The patent modifies physical and chemical parameters of the vancomycin formulation by adjusting pH, ionic strength, and lipid composition of the liposomal structure. These parameter changes create an optimized environment that reduces degradation rates while preserving antibiotic efficacy, resolving the stability-reliability contradiction.
2Reliability
If vancomycin is administered intravenously, then treatment of resistant infections is achieved, but toxicity concerns and high cost are incurred
Solution Approach 1:
The liposomal structure serves as an intermediary carrier between the vancomycin drug and the biological system. This intermediary protects host tissues from direct exposure to toxic effects of vancomycin while delivering the antibiotic to target sites, thereby reducing toxicity while maintaining treatment efficacy.
Solution Approach 2:
The patent divides the vancomycin formulation into discrete liposomal units with controlled size and composition. This segmentation allows for precise control of drug delivery, reducing off-target toxicity while maintaining effective concentration at infection sites, addressing the efficacy-toxicity contradiction.
3Stability of the object's composition
If vancomycin formulations are stabilized using amino acids, then degradation rate is reduced, but formulation complexity increases
Solution Approach 1:
The patent combines amino acid stabilization agents with liposomal vancomycin in a single integrated formulation. This merging approach achieves enhanced degradation resistance while consolidating multiple functional components into one cohesive system, reducing the practical complexity despite adding stabilization functionality.
Solution Approach 2:
The liposomal formulation serves multiple functions simultaneously: it provides structural stability, controls drug release, protects against degradation, and reduces toxicity. This multi-functionality achieves comprehensive stabilization without proportionally increasing complexity, as the same structural elements fulfill multiple protective roles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized composition significantly reduces degradation rates, maintaining at least 98% biological activity for extended periods, offering improved stability and efficacy in treating bacterial infections.
Implementation Method 1
the amino acid or derivative binds to the glycopeptide antibiotic and forms a stabilized glycopeptide antibiotic-amino acid complex
Implementation Method 2
the stabilized glycopeptide antibiotic-amino acid complex is entrapped by, or complexed with, the lipid component
Data Source
AI summary
In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.